Development of a novel proteinic adjuvant

2015 Fiscal Year Final Research Report

• Project/Area Number: 26660247
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Integrative animal science
• Research Institution: The University of Tokyo
• Principal Investigator: Goto Yasuyuki 東京大学, 農学生命科学研究科, 准教授 (50553434)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: ワクチン / アジュバント / MRP14

Outline of Final Research Achievements

Myeloid-related protein 14 (MRP14) is a protein expressed by immune cells including neutrophils and macrophages. In this study, we produced a recombinant MRP14 using an E. coli expression system and examined for its immunostimulatory activities and potency as an adjuvant for a flu vaccine. MRP14 displayed stimulatory activity on MΦ in vitro. It was revealed that MRP14 can serve as an agonist for multiple TLRs. Mice inoculated with a flu vaccine + MRP14 showed higher antibody titers than those with the vaccine alone. These suggest that MRP14 is a promising proteinic adjuvant.

Free Research Field

免疫学